Andrew Blank Biography and Net Worth

Director of BioCardia

Andrew Scott Blank is Chairman of our board of directors and was appointed to our board of directors in October 2019. Mr. Blank is President of National Brands, Inc., an investment group that was one of the largest Anheuser-Busch beer distributors prior to divestiture of those operations, and has served in that capacity since March 1993. Mr. Blank also currently serves as President of WareITis Technologies, developer of one of the foremost enterprise level content management software suites called Records Studio, President of Archive America, one of the country’s largest family-owned document storage firms, President of Seaboard Warehouse Terminals, Seaboard Chicago U.S. and Seaboard Warehouse, a group of companies providing nationwide third-party logistics services, and President of the Blank Family Foundation, a private family foundation that provides philanthropic support to worthy charitable organizations. Mr. Blank also currently serves on the board of directors of Neumentum, Inc. Mr. Blank holds a bachelor’s degree in business from the University of Miami.

What is Andrew Scott Blank's net worth?: The estimated net worth of Andrew Scott Blank is at least $672.06 thousand as of September 19th, 2025. Mr. Blank owns 634,023 shares of BioCardia stock worth more than $672,064 as of October 5th. This net worth estimate does not reflect any other assets that Mr. Blank may own. Learn More about Andrew Scott Blank's net worth.
How do I contact Andrew Scott Blank?: The corporate mailing address for Mr. Blank and other BioCardia executives is 320 Soquel Way, Sunnyvale, CA, 94085. BioCardia can also be reached via phone at (650) 226-0123 and via email at [email protected]. Learn More on Andrew Scott Blank's contact information.
Has Andrew Scott Blank been buying or selling shares of BioCardia?: Andrew Scott Blank has not been actively trading shares of BioCardia during the past quarter. Most recently, on Friday, September 19th, Andrew Scott Blank bought 288,000 shares of BioCardia stock. The stock was acquired at an average cost of $1.25 per share, with a total value of $360,000.00. Following the completion of the transaction, the director now directly owns 634,023 shares of the company's stock, valued at $792,528.75. Learn More on Andrew Scott Blank's trading history.
Who are BioCardia's active insiders?: BioCardia's insider roster includes Peter Altman (CEO), Andrew Blank (Director), Andrew Blank (Director), Edward Gillis (SVP), and David Mcclung (CFO). Learn More on BioCardia's active insiders.
Are insiders buying or selling shares of BioCardia?: In the last twelve months, BioCardia insiders bought shares 26 times. They purchased a total of 169,900 shares worth more than $162,947.00. The most recent insider tranaction occured on September, 29th when CEO Peter Altman bought 1,000 shares worth more than $1,030.00. Insiders at BioCardia own 17.4% of the company. Learn More about insider trades at BioCardia.
Information on this page was last updated on 9/29/2026.

Andrew Scott Blank Insider Trading History at BioCardia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/19/2025	Buy	288,000	$1.25	$360,000.00	634,023
6/30/2025	Buy	72,289	$2.08	$150,361.12	346,023

Andrew Scott Blank Buying and Selling Activity at BioCardia

BioCardia Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Today's Range

Now: $1.06

$1.04

$1.07

50 Day Range

MA: $1.02

$0.77

$1.25

2 Week Range

Now: $1.06

$0.75

$1.80

Volume

71,901 shs

Average Volume

1,125,218 shs

Market Capitalization

$16.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62